VTCN1 Antikörper (PerCP-Cy5.5)

Produktnummer ABIN2659922

Produktdetails anti-VTCN1 Antikörper (PerCP-Cy5.5)

Target: VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser VTCN1 Antikörper ist konjugiert mit PerCP-Cy5.5

Applikation: Flow Cytometry (FACS)

Aufreinigung: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Klon: MIH43

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu VTCN1

Target: VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))

Andere Bezeichnung: B7-H4 (VTCN1 Produkte)

Hintergrund: B7-H4, also known as VTCN1, is a type I transmembrane protein and member of the B7 family. Its extracellular region consists of one IgV-like and one IgC-like domain. B7-H4 expression has been reported on activated T cells, B cells, monocytes, and dendritic cells. On T cells, B7-H4 inhibits proliferation, cytokine secretion, and cytotoxicity. B7-H4 is also expressed by different carcinomas including renal, gastric, breast, ovarian and melanoma. Its expression is associated with a poor prognosis.